8-K: Owens & Minor to Acquire Rotech Healthcare Holdings, Expanding Home Healthcare Presence

Owens & Minor announces a definitive agreement to acquire Rotech Healthcare Holdings, aiming to strengthen its position in the high-growth home healthcare market.

Summary

• Owens & Minor (OMI) has entered into a definitive agreement to acquire Rotech Healthcare Holdings for $1.36 billion.
• The transaction is expected to close in the first half of 2025, pending FTC review and customary approvals.
• Rotech expands OMI's presence in the home healthcare market, complementing its existing businesses, Apria and Byram Healthcare.
• The acquisition is financed through $800 million in incremental term loan B, $600 million in other secured debt, and existing cash.
• The combined company is projected to have approximately $11.4 billion in revenue and $774 million in adjusted EBITDA for FY 2024.
• OMI is targeting deleveraging to below 3.0x net leverage after the acquisition.
• Potential run-rate cost savings of $50 million are expected by the end of year three.
• OMI is considering a potential sale of its Products & Healthcare Services segment.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the acquisition, highlighting strategic benefits, financial projections, and potential synergies. However, it also acknowledges risks and uncertainties associated with the transaction and integration, resulting in a moderately positive sentiment.

Positives

• The acquisition strengthens OMI's position in the high-growth home healthcare market.
• Rotech expands OMI's product offerings and provides access to the DME market.
• The transaction is expected to be accretive to operating and EBITDA margins.
• The combined company is expected to improve free cash flow generation.
• There is potential for $50 million in run-rate cost savings by the end of year three.
• The acquisition supports OMI's customer base and allows for better service to providers and payors.
• OMI has a track record of successful integrations with Byram, Halyard and Apria acquisitions.

Negatives

• The transaction increases OMI's debt, with an expected net leverage of approximately 4.2x at close.
• The acquisition is subject to FTC review, which could delay or prevent the closing.
• Integration of Rotech's business may present challenges and risks.
• OMI is considering a potential sale of its Products & Healthcare Services segment, creating uncertainty.

Risks

• The occurrence of any event, change or other circumstances that could give rise to the termination of the agreement relating to the proposed transaction.
• Risks related to disruption of management's attention from Owens & Minor's ongoing business operations due to the proposed transaction.
• The effect of the announcement of the proposed transaction on Owens & Minor's or Rotech's relationships with its customers, suppliers and other third parties, as well as operating results and their businesses generally.
• The risk that the proposed transaction will not be consummated in a timely manner or at all.
• Exceeding the expected costs of the transaction.
• The risk that problems may arise in successfully integrating the businesses of the companies, which may result in the combined company not operating as effectively and efficiently as expected.
• The risk that the combined company may be unable to achieve expected synergies or that it may take longer than expected to achieve those synergies.

Future Outlook

The company expects the acquisition to accelerate long-term revenue growth, be accretive to operating and EBITDA margins, improve free cash flow generation, and be accretive to Adjusted EPS. OMI is targeting deleveraging to below 3.0x net leverage after the acquisition and expects $50 million in potential run-rate cost savings by the end of year three.

Management Comments

• OMI is a global healthcare solutions company integrating product manufacturing and delivery, home health supply and perioperative services to support care through the hospital and into the home.
• The Transaction is intended to create a more competitive, faster-growing and more diversified company.

Industry Context

The acquisition reflects a broader trend of consolidation in the healthcare industry, particularly in the home healthcare market, driven by an aging population, increasing prevalence of chronic diseases, and a shift towards value-based care models. Companies are seeking to expand their product offerings and geographic reach to better serve patients and providers across the continuum of care.

Comparison to Industry Standards

• The document does not provide specific comparisons to industry standards.
• However, the acquisition of Rotech is in line with industry trends of consolidation and expansion in the home healthcare market.
• Comparable companies in the home healthcare space include AdaptHealth, Lincare, and Apria Healthcare (already owned by Owens & Minor).

Stakeholder Impact

• Shareholders: Potential for increased revenue, earnings, and shareholder value.
• Employees: Integration of Rotech's employees into Owens & Minor, with potential for synergies and cost savings.
• Customers: Expanded product offerings and improved service for patients with chronic conditions.
• Suppliers: Potential for increased volume and expanded relationships.
• Payors: Supports combined customer base across an integrated national network to better serve providers, payors and suppliers.

Next Steps

• Obtain FTC approval and satisfy customary closing conditions.
• Close the transaction in the first half of 2025.
• Integrate Rotech's business into Owens & Minor's Patient Direct segment.
• Achieve $50 million in run-rate cost savings by the end of year three.
• Deleverage to below 3.0x net leverage.
• Potentially sell the Products & Healthcare Services segment.

Key Dates

Keywords

acquisition, Rotech Healthcare, Owens & Minor, home healthcare, DME, EBITDA, net leverage, synergies, Apria, Byram